360 related articles for article (PubMed ID: 31953320)
21. A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.
Song Y; Zhao M; Wu Y; Yu B; Liu HM
Acta Pharm Sin B; 2021 Mar; 11(3):750-762. PubMed ID: 33777680
[TBL] [Abstract][Full Text] [Related]
22. Identification of demethylincisterol A
Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
[TBL] [Abstract][Full Text] [Related]
23. Induction of a tumor-associated activating mutation in protein tyrosine phosphatase Ptpn11 (Shp2) enhances mitochondrial metabolism, leading to oxidative stress and senescence.
Zheng H; Li S; Hsu P; Qu CK
J Biol Chem; 2013 Sep; 288(36):25727-25738. PubMed ID: 23884424
[TBL] [Abstract][Full Text] [Related]
24. Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening.
Yu ZH; Chen L; Wu L; Liu S; Wang L; Zhang ZY
Bioorg Med Chem Lett; 2011 Jul; 21(14):4238-42. PubMed ID: 21669525
[TBL] [Abstract][Full Text] [Related]
25. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition.
LaRochelle JR; Fodor M; Vemulapalli V; Mohseni M; Wang P; Stams T; LaMarche MJ; Chopra R; Acker MG; Blacklow SC
Nat Commun; 2018 Oct; 9(1):4508. PubMed ID: 30375388
[TBL] [Abstract][Full Text] [Related]
26. Targeting SHP2 phosphatase in hematological malignancies.
Kanumuri R; Kumar Pasupuleti S; Burns SS; Ramdas B; Kapur R
Expert Opin Ther Targets; 2022 Apr; 26(4):319-332. PubMed ID: 35503226
[TBL] [Abstract][Full Text] [Related]
27. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
Yuan X; Bu H; Zhou J; Yang CY; Zhang H
J Med Chem; 2020 Oct; 63(20):11368-11396. PubMed ID: 32460492
[TBL] [Abstract][Full Text] [Related]
28. Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2.
Chio CM; Lim CS; Bishop AC
Biochemistry; 2015 Jan; 54(2):497-504. PubMed ID: 25519989
[TBL] [Abstract][Full Text] [Related]
29. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Liu X; Zheng H; Li X; Wang S; Meyerson HJ; Yang W; Neel BG; Qu CK
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):984-9. PubMed ID: 26755576
[TBL] [Abstract][Full Text] [Related]
30. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
[TBL] [Abstract][Full Text] [Related]
31. Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation.
Zhu G; Xie J; Kong W; Xie J; Li Y; Du L; Zheng Q; Sun L; Guan M; Li H; Zhu T; He H; Liu Z; Xia X; Kan C; Tao Y; Shen HC; Li D; Wang S; Yu Y; Yu ZH; Zhang ZY; Liu C; Zhu J
Cell; 2020 Oct; 183(2):490-502.e18. PubMed ID: 33002410
[TBL] [Abstract][Full Text] [Related]
32. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
Zhang X; He Y; Liu S; Yu Z; Jiang ZX; Yang Z; Dong Y; Nabinger SC; Wu L; Gunawan AM; Wang L; Chan RJ; Zhang ZY
J Med Chem; 2010 Mar; 53(6):2482-93. PubMed ID: 20170098
[TBL] [Abstract][Full Text] [Related]
33. Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2.
LaRochelle JR; Fodor M; Ellegast JM; Liu X; Vemulapalli V; Mohseni M; Stams T; Buhrlage SJ; Stegmaier K; LaMarche MJ; Acker MG; Blacklow SC
Bioorg Med Chem; 2017 Dec; 25(24):6479-6485. PubMed ID: 29089257
[TBL] [Abstract][Full Text] [Related]
34. Small-molecule Modulators Targeting SHP2 for Cancer Therapy.
Mi D; Li Y; Chen Y
Anticancer Agents Med Chem; 2023; 23(5):498-504. PubMed ID: 36154594
[TBL] [Abstract][Full Text] [Related]
35. The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/β-catenin signaling pathway.
Zhang Q; Li Y; Zhao R; Wang X; Fan C; Xu Y; Liu Y; Li J; Wang S
Mol Carcinog; 2018 May; 57(5):619-628. PubMed ID: 29323748
[TBL] [Abstract][Full Text] [Related]
36. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
Kerr DL; Haderk F; Bivona TG
Curr Opin Chem Biol; 2021 Jun; 62():1-12. PubMed ID: 33418513
[TBL] [Abstract][Full Text] [Related]
37. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
[TBL] [Abstract][Full Text] [Related]
38. From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement.
Mostinski Y; Heynen GJJE; López-Alberca MP; Paul J; Miksche S; Radetzki S; Schaller D; Shanina E; Seyffarth C; Kolomeets Y; Ziebart N; de Schryver J; Oestreich S; Neuenschwander M; Roske Y; Heinemann U; Rademacher C; Volkamer A; von Kries JP; Birchmeier W; Nazaré M
J Med Chem; 2020 Dec; 63(23):14780-14804. PubMed ID: 33210922
[TBL] [Abstract][Full Text] [Related]
39. Development and structure-activity relationship study of SHP2 inhibitor containing 3,4,6-trihydroxy-5-oxo-5H-benzo[7]annulene.
Kim B; Jo S; Park SB; Chae CH; Lee K; Koh B; Shin I
Bioorg Med Chem Lett; 2020 Jan; 30(1):126756. PubMed ID: 31784318
[TBL] [Abstract][Full Text] [Related]
40. Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds.
Guo W; Xu Q
J Pharmacol Sci; 2020 Nov; 144(3):139-146. PubMed ID: 32921395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
